Thursday, 16 Aug 2018

You are here

Top 16 Drugs in Rheumatology 2016

Using data compiled from annual reports, SEC filings, press releases, company websites, recently released sales figures show that in 2016, 11 of the top 16 rheumatology drugs demonstrated blockbuster sales (>$1 billion per annum).  Highlights from this report include:

  • TNF inhibitors – the big three TNFi (ADA, ETN, INF) lead the way with $33.7 billion in 2016.  Humira continued as the worldwide leader in sales $16.1 billion.  Sales of all 5 TNFi totaled $37.9 billion.  While Humira growth (15%) continues, Enbrel has flattened (2%) and Remicade has declined (-2%).
  • Greatest growth from 2015 to 2016 was Cosentyx (332% to $1.1 billion in 2016), Otezla (116% to $1 billion) and Xeljanz (77% to $927 million).
  • Greatest losses were seen for NSAID market, with -12% drop for Celebrex, -4% drop for Arcoxia (Cox-2 inhibitor sold outside the USA) and a -2% drop for aspirin.
  • Psoriatic arthritis therapeutic market was hot with substantial growth by Cosentyx (332%), Otezla (116%) and Stelara (31%), in addition to TNF inhibitor growth.

TOP 16 RHEUMATOLOGY DRUGS – 2016 SALES

 

Brand

Generic

2015 Sales*

2016 Sales*

Growth Rate

1

Humira

Adalimumab

14012

16078

15%

2

Enbrel

Etanercept

8697

8874

2%

3

Remicade

Infliximab

8791

8789

-2%

4

Rituxan

Rituximab

5584

5765

3%

5

Stelara

Ustekinumab

2474

3232

31%

6

Simponi

Golimumab

2133

2719

27%

7

Orencia

Abatacept

1957

.2368

21%

8

Actemra

Tocilizumab

1432

1697

19%

9

Cimzia

Certolizumab

1191

1438

21%

10

Cosentyx

Secukinumab

261

1128

332%

11

Otezla

Apremilast

472

1017

116%

12

Xeljanz

Tofacitinib

523

927

77%

13

Celebrex

Celcoxib

830

733

-12%

14

Aspirin

Aspirin

525

513

-2%

15

Arcoxia

Etoricoxib

471

450

-4%

16

Ilaris

Canakinumab

236

283

20%

* Worldwide sales expressed millions (USD)

Add new comment

More Like This

Opioid Aversion is Augmenting Spinal Steroid Injections

As physicians turn away from opioids, are they resorting to options that may also be unsafe?

The New York Times reports that some physicians are using the anti-inflammatory drug, Depo-Medrol, for intraspinal injections to manage painful spinal and perispinal disorders.

Company Payments to Rheumatologists, Specialists Linked to Increased ACTH Prescriptions

Despite its exorbitant price tag and paucity of supportive clinical evidence, ACTH (corticotropin) sales have increased in the United States. A recent JAMA article examined its use by specialists and found that those who prescribe ACTH (including rheumatologists, nephrologists, neurologists) received corticotropin-related payments from the products sole manufacturer, Mallinckrod.

Veterans Administration Shuns Marijuana as an Option

Cannabis therapy is legal in 30 states in the US, and soon to be legal in Canada and Great Britian, but the US Veterans Administration continues to reject medical marijuana as a therapeutic option - even in states where it is approved.

Predictors of Methotrexate Non-Response

New research from a UK study suggests that nonresponse to oral or subcutaneous MTX was seen in 43% and is predicted by seronegativity, higher disease activity measures and higher anxiety scores.

Best of 2017: New EULAR Guidelines on Behçet's

At the EULAR 2016 meeting, new EULAR recommendations for the management of Behçet's disease (BD) were presented. These were developed by a multidisciplinary expert committee that reviewed the evidence from the medical literature and developed final set of 9 recommendations: